OKYO Pharma Limited's Presentation at BIO-Europe 2025
OKYO Pharma Limited (NASDAQ: OKYO) has confirmed an important presentation at the upcoming BIO-Europe partnering conference. This significant international event will take place at the Vienna Congress and Convention Center, presenting a unique opportunity for the company to showcase its advancements. Dr. Gary S. Jacob, the Chief Executive Officer, will detail initiatives focused on neuropathic corneal pain during the sessions.
The Significance of BIO-Europe 2025
BIO-Europe is recognized as one of the largest and most impactful partnering events in the life sciences sector. Scheduled for November 3-5, 2025, this conference attracts global leaders and innovators dedicated to advancing collaborations in the biopharmaceutical industry. Dr. Jacob's participation signifies OKYO's commitment to addressing urgent medical needs in ocular health.
Showcasing Urcosimod
During the conference, Dr. Jacob will present updates regarding OKYO’s lead investigational candidate, urcosimod. This candidate has shown promise, especially following the successful completion of its Phase 2 clinical trials aimed at treating neuropathic corneal pain. The attention surrounding urcosimod is paramount as it represents a potential breakthrough in treatments for a condition that currently lacks FDA-approved options.
OKYO's Ongoing Clinical Trials
The management team at OKYO will not only focus on the presentation; they will also conduct one-on-one partnering meetings throughout the conference. These discussions are pivotal as they outline recent positive clinical data for urcosimod and detail the expedited progress of its clinical development program. Engaging with potential partners can catalyze further advancements in OKYO's therapeutic applications.
Understanding Neuropathic Corneal Pain (NCP)
Neuropathic corneal pain (NCP) is characterized by severe discomfort affecting the eyes, face, and head. The underlying cause remains poorly understood but often relates to nerve damage within the corneal region coupled with inflammation. Currently, treatment options for NCP are limited, with varying success rates from off-label topical and systemic therapies. The innovation behind urcosimod aims to provide a more effective solution for those suffering from this debilitating condition.
About Urcosimod
Urcosimod, previously known as OK-101, acts as a peptide agonist targeting the ChemR23 receptor linked to immune responses in the ocular environment. This agent is uniquely designed to offer lasting action and has demonstrated notable anti-inflammatory effects in preclinical models of dry eye disease and corneal pain. Positive outcomes from a 240-patient Phase 2 study have propelled urcosimod towards further evaluation, potentially revolutionizing treatment options for NCP.
Company Overview: OKYO Pharma Limited
OKYO Pharma Limited (NASDAQ: OKYO) is advancing innovative therapies tailored for treating neuropathic corneal pain and dry eye diseases. With its shares traded on the NASDAQ Capital Market, OKYO is devoted to developing new therapeutic molecules aimed at enhancing patient care in ophthalmic conditions. The company not only focuses on its rich pipeline, but also seeks to engage with key stakeholders to facilitate growth and development.
Contact OKYO Pharma for More Information
For additional information regarding OKYO's initiatives and upcoming developments, you can reach out directly to the leadership team:
OKYO Pharma Limited
Gary S. Jacob, Chief Executive Officer
Phone: +44 (0)20 7495 2379
Investor Relations Contact: Paul Spencer
Phone: +44 (0)20 7495 2379
Frequently Asked Questions
What is the main focus of OKYO Pharma's presentation at BIO-Europe?
The presentation will focus on urcosimod, an investigational candidate aimed at treating neuropathic corneal pain.
When and where is the BIO-Europe conference taking place?
The BIO-Europe conference is scheduled for November 3-5, 2025, at the Vienna Congress and Convention Center.
What is neuropathic corneal pain?
Neuropathic corneal pain is a severe ocular pain condition caused by nerve damage and inflammation that currently lacks FDA-approved treatments.
Who is the CEO of OKYO Pharma?
The CEO of OKYO Pharma is Gary S. Jacob, Ph.D.
How can I reach OKYO Pharma for more details?
You can contact OKYO Pharma by calling +44 (0)20 7495 2379 for inquiries and further information.
